These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36484956)

  • 1. Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia.
    Furuya C; Hashimoto Y; Morishita S; Inano T; Ochiai T; Shirane S; Edahiro Y; Araki M; Ando M; Komatsu N
    J Thromb Thrombolysis; 2023 Feb; 55(2):263-272. PubMed ID: 36484956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.
    Haider M; Gangat N; Lasho T; Abou Hussein AK; Elala YC; Hanson C; Tefferi A
    Am J Hematol; 2016 Jun; 91(4):390-4. PubMed ID: 26799697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
    Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
    Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
    Pérez Encinas MM; Sobas M; Gómez-Casares MT; Abuin Blanco A; Noya Pereira MS; Raya JM; Andrade-Campos MM; Álvarez Larrán A; Lewandowski K; Łukasz S; Hernández Boluda JC; Ferrer-Marín F; Fox ML; Gołos A; Gasior Kabat M; Magro Mazo E; Czyż A; Martín Martín A; Bellosillo Paricio B; Quinteiro García C; González Martín JM; Stuckey R
    Eur J Haematol; 2021 Mar; 106(3):371-379. PubMed ID: 33275803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
    Carobbio A; Thiele J; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Vannucchi AM; Antonioli E; Gisslinger H; Buxhofer-Ausch V; Finazzi G; Gangat N; Tefferi A; Barbui T
    Blood; 2011 Jun; 117(22):5857-9. PubMed ID: 21490340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.
    Santoro M; Accurso V; Mancuso S; Carlisi M; Raso S; Tarantino G; Di Piazza F; Perez A; Russo A; Siragusa S
    Hematol Oncol; 2019 Oct; 37(4):434-437. PubMed ID: 31465530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis.
    Yang E; Wang M; Wang Z; Li Y; Wang X; Ming J; Xiao H; Quan R; Liu W; Hu X
    Ann Hematol; 2021 Nov; 100(11):2699-2706. PubMed ID: 34383101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients.
    Fu R; Xuan M; Lv C; Zhang L; Li H; Zhang X; Zhang D; Sun T; Xue F; Liu X; Liang H; Zhang L; Yang R
    Eur J Haematol; 2014 Jun; 92(6):502-9. PubMed ID: 24460750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.
    Qin Y; Wang X; Zhao C; Wang C; Yang Y
    Int J Hematol; 2015 Aug; 102(2):170-80. PubMed ID: 25997869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
    Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
    Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical Characteristics and Long-Term Outcome of 125 Chinese Young Patients with Essential Thrombocythemia].
    Fu RF; Liu XF; Liu W; Huang YT; Chen YF; Li HY; Ju MK; Yang RC; Zhang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):837-842. PubMed ID: 28641646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia.
    Lekovic D; Gotic M; Milic N; Miljic P; Mitrovic M; Cokic V; Elezovic I
    Med Oncol; 2014 Oct; 31(10):231. PubMed ID: 25223529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service.
    Navarro LM; Trufelli DC; Bonito DR; Del Giglio A; Bollmann PW
    Rev Assoc Med Bras (1992); 2016 Oct; 62(7):647-651. PubMed ID: 27925044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea.
    Lee HS; Park LC; Lee EM; Lee SJ; Shin SH; Im H; Do KM; Kim EJ; Ye BJ; Song MK; Kim SH; Lee SM; Lee WS; Kim YS
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):70-5. PubMed ID: 22088920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.
    Yang Y; Wang X; Wang C; Qin Y
    Int J Hematol; 2015 Feb; 101(2):165-72. PubMed ID: 25540065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).
    Barbui T; Finazzi G; Carobbio A; Thiele J; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Gisslinger H; Buxhofer-Ausch V; De Stefano V; Betti S; Rambaldi A; Vannucchi AM; Tefferi A
    Blood; 2012 Dec; 120(26):5128-33; quiz 5252. PubMed ID: 23033268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.